- Home | Ferrer
Noticias Ferrer strengthens its impact in 2024 with increased social and environmental investment, B Corp leadership and sustainability progress Ver más
- Inicio | Ferrer
Nature Medicine publica datos de un ensayo de fase 3 sobre la pridopidina en enfermedad de Huntington en fase temprana, destacando su impacto en la progresión clínica Ver más Noticias Ferrer refuerza su impacto en 2024 con más inversión social y ambiental, liderazgo B Corp y avances en sostenibilidad Ver más
- Contact - Ferrer
You can also contact your local subsidiary Germany Ferrer Deutschland GmbH Kaiserstraße, 100 D-52134, Herzogenrath (Alemania)
- Pharmaceuticals | Ferrer
In order to provide significant differential value to people suffering from serious illnesses, at Ferrer, we have established a clear global strategy to develop a portfolio of innovative products capable of transforming the lives of patients suffering from severe and debilitating diseases
- Ferrer for good
Ferrer is the first Spanish pharma company to be part of the B Corp Community With 136 4 points, Ferrer is the highest-rated pharmaceutical B Corp in the world
- Ferrer obtains the distribution rights of a potential treatment for . . .
Under the expanded agreement, Ferrer has been appointed as the exclusive, worldwide distributor (except for the US, Canada, Japan, China, and Israel), to make this therapeutic option available upon approval for the treatment of IPF and PPF and keep delivering transformative solutions to the patients in need
- Ferrer US
Ferrer US is focused on the research and development of novel, proprietary products for the acute treatment of underserved medical needs, in the therapeutic areas of neurodegenerative disorders and pulmonary and interstitial lung disease
- We complete recruitment of 220 patients for the PROSPER . . . - ferrer. com
Ferrer is an international company based in Barcelona, strongly committed to the research and development of innovative therapies in areas of high unmet medical need, such as rare neurological diseases and pulmonary vascular and interstitial diseases
|